Most Down Articles

Published in last 1 year|In last 2 years|In last 3 years|All|Most Downloaded in Recent Month|Most Downloaded in Recent Year|

In last 2 years

Please wait a minute...


For Selected: Download Citations EndNote Ris BibTeX Toggle Thumbnails

Select

Journal of International Oncology 2025, 52 (1): 3-22. DOI:10.3760/cma.j.cn371439-20250103-00002 Abstract（ 1081） HTML（ 40） PDF（pc）（2876KB）（ 805） Knowledge map Save Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2024, 51 (7): 385-410. DOI:10.3760/cma.j.cn371439-20240415-00067 Abstract（ 209） HTML（ 25） PDF（pc）（1545KB）（ 775） Knowledge map Save Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Chinese expert consensus on the diagnosis and treatment of cancer-related anorexia Chinese Society of Clinical Oncology-Supportive Care and Rehabilitation Committee, Chinese Expert Consensus Working Group on Cancer-related Anorexia Journal of International Oncology 2025, 52 (2): 67-78. DOI:10.3760/cma.j.cn371439-20241223-00011 Abstract（ 283） HTML（ 14） PDF（pc）（1970KB）（ 519） Knowledge map Save Cancer-related anorexia refers to the loss or reduction of appetite caused by cancer itself and/or anticancer treatments. This condition encompasses a spectrum of symptoms， including anorexia， nausea， gustatory alteration， early satiety or dysphagia，etc. Cancer-related anorexia not only affects the nutritional status of patients， but is also closely associated with severe adverse outcomes， such as reduced survival， decreased compliance with anti-tumor treatment， increased treatment-related side effects， and diminished quality of life. Despite its widespread prevalence among patients and the urgency of its prevention and treatment， the understanding and management of both doctors and patients need to be further deepened and improved. Recognizing these challenges， Chinese Society of Clinical Oncology-Supportive Care and Rehabilitation Committee convened a panel of experts across relevant fields in China to summarize the screening and diagnosis criteria of cancer-related anorexia based on the current status of clinical practice and the existing research evidence， and to systematically propose a comprehensive management strategy. This consensus will become an important reference for clinicians in the diagnosis and treatment of cancer-related anorexia， which can better standardize the diagnosis and treatment measures for cancer-related anorexia， achieve active screening， early intervention and standardized treatment， so as to benefit more patients. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Current situation and countermeasure of overdiagnosis and overtreatment of pulmonary ground-glass nodule Liang Xinyu, Wei Zhigang, Ye Xin Journal of International Oncology 2024, 51 (7): 432-440. DOI:10.3760/cma.j.cn371439-20240509-00071 Abstract（ 210） HTML（ 22） PDF（pc）（879KB）（ 479） Knowledge map Save Lung cancer has emerged as one of the most prevalent malignant diseases globally， characterized by the highest incidence and mortality rates. Thus， early detection， diagnosis， and treatment play crucial roles in reducing the mortality associated with lung cancer. Research has revealed that low-dose computed tomography （LDCT） screening significantly reduces the mortality rate of lung cancer among high-risk populations. Nevertheless， the expansion of LDCT screening initiatives has led to an increased detection of asymptomatic pulmonary ground-glass nodule （GGN）. This heightened detection rate may result in overdiagnosis， overtreatment， inappropriate utilization of medical resources， and heightened anxiety amongst patients. Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2024, 51 (1): 1-20. DOI:10.3760/cma.j.cn371439-20231221-00001 Abstract（ 507） HTML（ 94） PDF（pc）（2788KB）（ 433） Knowledge map Save Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Relationship between Vav3 and malignant tumors Shi Xuebing, Wu Jing, Deng Wenxia Journal of International Oncology 2024, 51 (9): 585-589. DOI:10.3760/cma.j.cn371439-20240215-00097 Abstract（ 176） HTML（ 43） PDF（pc）（695KB）（ 395） Knowledge map Save Vav guanine nucleotide exchange factor 3 （Vav3） protein is one of the guanine nucleotide exchange factors of the Rho family GTPases. It is encoded by the proto-oncogene Vav3 and is involved in the regulation of cell proliferation and apoptosis， differentiation， migration，etc. In recent years， Vav3 has been closely related to the development of a variety of malignant tumors. In glioma， breast cancer， non-small cell lung cancer， gastric cancer， pancreatic cancer， colorectal cancer， prostate cancer， ovarian cancer， osteosarcoma and acute leukemia， the expression of Vav3 is elevated to varying degrees， and it participates in regulating multiple signaling pathways， which promotes the progression of tumors and affects the prognosis of patients. Therefore， Vav3 is expected to be a potential therapeutic target for these malignant tumors. Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2024, 51 (9): 0-0. Abstract（ 102） PDF（pc）（3150KB）（ 234） Knowledge map Save Related Articles|Metrics|Comments（0）

Select

Research progress in immunotherapy and targeted therapy for gastric cancer and esophagogastric junction cancer Wu Yang, Li Tian, Zhang Runbing, Shi Tingting, Gao Chun, Zheng Xiaofeng, Zhang Jiucong Journal of International Oncology 2024, 51 (9): 595-600. DOI:10.3760/cma.j.cn371439-20240716-00099 Abstract（ 293） HTML（ 136） PDF（pc）（715KB）（ 230） Knowledge map Save Gastric cancer and esophagogastric junction cancer （EGJC） are one of the world's most common types of malignant tumors. Traditional treatment methods mainly include radiotherapy， chemotherapy， and surgery， but the patients'prognosis is limited. In recent years， with the development in treatment methods， immunotherapy and targeted therapy are gradually recognized as the first-line treatment methods. In immunotherapy， nivolumab and pabolizumab have shown clear efficacy in patients with programmed death-ligand 1 positive， while other immunotherapies （such as tumor vaccine， engineered T cells， and non-specific immunomodulators） are still being tested or developed. In addition， targeted therapy has only shown comparatively large therapeutic potential in certain specific populations or in second-line treatment. For instance， tratuzumab has a clear curative effect on patients with positive human epidermal growth factor receptor 2， but has suboptimal efficacy in patients with amplification of other molecular targets. An in-depth discussion of the research progress of immunotherapy and targeted therapy in gastric cancer and EGJC will help to improve the prognosis of patients and provide a reference for accurate treatment of tumors. Reference|Related Articles|Metrics|Comments（0）

Select

Effects of ALKBH5 on the malignant biological behavior of esophageal squamous cell carcinoma and the related mechanism Ma Peihan, Zhang Lingmin, Li Qian, Lu Ning, Wen Hua, Zhang Mingxin Journal of International Oncology 2025, 52 (2): 79-88. DOI:10.3760/cma.j.cn371439-20240607-00012 Abstract（ 166） HTML（ 18） PDF（pc）（3611KB）（ 226） Knowledge map Save ObjectiveTo investigate the role and potential mechanism of m6A demethylase ALKBH5 in esophageal squamous cell carcinoma （ESCC）.MethodsReal time fluorogenic quantitative PCR and Western blotting were used to detect ALKBH5 expression in normal esophageal epithelial cells （Het-1A） and ESCC cell lines （Eca109， KYSE30， KYSE150， KYSE410）. Transient cell lines with overexpression/knockdown of ALKBH5 （siRNA transfection was divided into si-ALKBH5-1 group and si-ALKBH5-2 group） and control cell lines were constructed. The effects of ALKBH5 on ESCC cell proliferation， migration and apoptosis were studied by MTT assay， cell scratch assay and cell apoptosis assay respectively. The differentially expressed gene was screened by the intersection of RNA sequencing （RNA-seq） and methylated RNA immunoprecipitation sequencing （MeRIP-seq） techniques， and the effect of ALKBH5 on the gene expression was detected by RT-qPCR.ResultsReal time fluorogenic quantitative PCR results showed that， the relative expression levels of ALKBH5 RNA in Het-1A， Eca109， KYSE30， KYSE150 and KYSE410 were 1.03±0.28， 0.46±0.02， 0.23±0.10， 0.04±0.02， 0.05±0.00， respectively， with a statistically significant difference （F=444.60，P<0.001）. Western blotting showed that， the relative expression levels of ALKBH5 protein in Het-1A， Eca109， KYSE30， KYSE150 and KYSE410 were 1.14±0.03， 0.88±0.04， 0.66±0.01， 0.69±0.01， 0.95±0.01， respectively， with a statistically significant difference （F=139.90，P<0.001）. MTT test showed that the absorbance （A） values of KYSE30 control group and ALKBH5 overexpression group were 0.86±0.01 and 1.25±0.01 after 72 hours， respectively， with a statistically significant difference （t=46.93，P<0.001）. TheAvalues of KYSE150 control group and ALKBH5 overexpression group were 1.00±0.03 and 1.43±0.02 after 72 hours， respectively， with a statistically significant difference （t=16.80，P<0.001）. TheAvalues of KYSE30 control group， si-ALKBH5-1 group and si-ALKBH5-2 group were 0.98±0.01， 0.85±0.02 and 0.80±0.09 after 96 hours， respectively， with a statistically significant difference （F=72.97，P<0.001）. TheAvalues of KYSE30 control group were higher than those of si-ALKBH5-1 and si-ALKBH5-2 groups （bothP<0.001）. TheAvalues of KYSE410 control group， si-ALKBH5-1 group and si-ALKBH5-2 group were 1.28±0.02， 1.15±0.02 and 1.08±0.05 after 72 hours， respectively， with a statistically significant difference （F=16.97，P=0.003）. TheAvalues in KYSE410 control group were higher than those in si-ALKBH5-1 group and si-ALKBH5-2 group （P=0.020；P=0.003）. The cell scratch test showed that 48 hours after scratch， the migration rates of KYSE30 cells in control group and ALKBH5 overexpression group were （27.39±0.54）% and （48.89±5.12）%， respectively， with a statistically significant difference （t=5.90，P=0.004）. The migration rates of KYSE150 cells in control group and ALKBH5 overexpression group were （39.67±0.43）% and （62.20±0.60）%， respectively， with a statistically significant difference （t=43.15，P<0.001）. The migration rates of KYSE30 cells in control group， si-ALKBH5-1 group and si-ALKBH5-2 group were （25.08±1.86）%， （18.75±1.59）% and （7.67±0.52）%， respectively， with a statistically significant difference （F=74.28，P<0.001）. The migration rates of KYSE30 cells in control group were higher than those of si-ALKBH5-1 group and si-ALKBH5-2 group （P=0.010；P<0.001）. The migration rates of KYSE410 cells in control group and si-ALKBH5-1 group， si-ALKBH5-2 group were （38.70±0.41）%， （28.27±1.01）% and （19.40±0.47）%， respectively， with a statistically significant difference （F=400.20，P<0.001）. The migration rates of KYSE410 cells in control group were higher than those of si-ALKBH5-1 group and si-ALKBH5-2 group （bothP<0.001）. Apoptosis test showed that the apoptosis rates of KYSE30 cells in control group and ALKBH5 overexpression group were （9.59±0.88）% and （4.81±0.89）%， respectively， with a statistically significant difference （t=6.23，P=0.006）. The apoptosis rates of KYSE150 cells in control group and ALKBH5 overexpression group were （8.36±0.09）% and （6.42±0.19）%， respectively， with a statistically significant difference （t=12.90，P<0.001）. The apoptosis rates of KYSE30 cells in control group， si-ALKBH5-1 group and si-ALKBH5-2 group were （4.31±0.19）%， （5.72±0.30）% and （8.94±0.71）%， respectively， with a statistically significant difference （F=53.46，P<0.001）. The apoptosis rates in KYSE30 cells in control group were lower than those in si-ALKBH5-1 group and si-ALKBH5-2 group （P=0.049；P<0.001）. The apoptosis rates of KYSE410 control group， si-ALKBH5-1 group and si-ALKBH5-2 group were （4.45±0.36）%， （5.40±0.11）% and （6.64±0.15）%， respectively， with a statistically significant difference （F=43.36，P<0.001）. The apoptosis rates in KYSE410 cells in control group were lower than those in si-ALKBH5-1 group and si-ALKBH5-2 group （P=0.016；P<0.001）. The differentially expressed gene IGF2BP3 was screened by the intersection of RNA-seq and MeRIP-seq techniques， and the RT-qPCR results showed that， the relative expression levels of IGF2BP3 in KYSE30 were 1.01±0.10 and 1.41±0.10 in control group and ALKBH5 overexpression group， respectively， with a statistically significant difference （t=4.06，P=0.015）. The relative expression levels of IGF2BP3 in KYSE150 were 1.00±0.10 and 1.94±0.24 in control group and ALKBH5 overexpression group， respectively， with a statistically significant difference （t=5.08，P=0.007）. The relative expression levels of IGF2BP3 in KYSE410 were 1.01±0.14， 0.67±0.04 and 0.41±0.04 in control group， si-ALKBH5-1 group and si-ALKBH5-2 group， respectively， with a statistically significant difference （F=24.36，P=0.001）. The relative expression levels of IGF2BP3 in KYSE410 control group were higher than those in si-ALKBH5-1 group and si-ALKBH5-2 group （P=0.017；P=0.001）.ConclusionsALKBH5 is underexpressed in ESCC cell lines， but the overexpression of ALKBH5 can promote the proliferation and migration of ESCC cells and inhibit cell apoptosis， which may be related to some negative feedback regulation mechanism. IGF2BP3 may be the downstream target of ALKBH5. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2025, 52 (2): 65-66. DOI:10.3760/cma.j.cn371439-20240621-00010 Abstract（ 116） HTML（ 7） PDF（pc）（755KB）（ 224） Knowledge map Save Reference|Related Articles|Metrics|Comments（0）

Select

Research progress of habitat analysis in radiomics of malignant tumors Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying Journal of International Oncology 2024, 51 (5): 292-297. DOI:10.3760/cma.j.cn371439-20240108-00049 Abstract（ 394） HTML（ 29） PDF（pc）（722KB）（ 214） Knowledge map Save Nowadays， the research on traditional radiomics has gradually matured. However， it usually regards the tumor as a whole， and high-throughput data are often generated in the entire tumor region， which cannot express clear spatial heterogeneity. In order to explore the potential biological information within tumors and realize individualized precise diagnosis and treatment， habitat analysis technology emerges at the historic moment， which provides a new way of thinking to identify tumor microenvironment. On the basis of traditional radiomics， the tumor cell population with similar characteristics is clustered， and the tumor is segmented into multiple sub-regions. Therefore， the study of tumor is no longer limited by the subjective differences of observers in the description of imaging features， and the information of tumor spatial heterogeneity is ideally obtained. Reference|Related Articles|Metrics|Comments（0）

Select

Pattern of lymph node metastasis in the lung lobe of NSCLC and selection of lymph node dissection methods in complete video-assisted thoracoscopic lobectomy surgery Wang Qingbei, Zhu Lin, Wu Zhengguo Journal of International Oncology 2024, 51 (9): 569-577. DOI:10.3760/cma.j.cn371439-20240422-00095 Abstract（ 180） HTML（ 40） PDF（pc）（1378KB）（ 186） Knowledge map Save ObjectiveTo explore the pattern of lymph node metastasis in the lung lobes of stage Ⅱa non-small cell lung cancer （NSCLC） and the lymph node dissection method during complete video-assisted thoracoscopic lobectomy surgery （cVATS）.MethodsA total of 244 patients with NSCLC who underwent cVATS treatment at Nanjing Tongren Hospital Affiliated to Southeast University School of Medicine from January 2015 to November 2018 were selected. Patients admitted from January 2015 to April 2018 were defined as the training set （n=183）， and patients admitted from May 2018 to November 2018 were defined as the validation set （n=61）. The training set was used to build the model， and the validation set was used to evaluate the performance of the model. In the training set， patients were divided into systematic meditational lymphadenectomy （SML） group （n=93） and lobe-specific systematic node dissection （LSND） group （n=90） based on lymph node dissection methods.The lymph node metastasis rate of patients in the training set was calculated， and the clinical data of patients with （n=55） and without （n=128） lymph node metastasis were compared. Multivariate logistic regression was used to analyze the influencing factors of lymph node metastasis， and a nomogram prediction model was constructed based on the results of the multivariate analysis， and the model was validated. Clinical data， perioperative clinical indicators， overall survival （OS）， and incidence of postoperative complications were compared between the SML group and LSND group in the training set.ResultsIn the training set， the lymph node metastasis rate of 183 patients with NSCLC was 30.05% （55/183）， with a total of 328 metastatic lymph nodes； from the 2nd to the 13th groups of lymph nodes， the 10th （15.60%， 44/282）， the 11th （22.79%， 98/430）， and the 12th to the 13th （15.25%， 61/400） groups had the highest lymph node metastasis rate. Multivariate analysis showed that maximum tumor diameter （OR=2.71， 95%CI： 1.82-4.09，P<0.001）， CT imaging features （OR=2.49， 95%CI： 1.59-6.99，P=0.001）， degree of differentiation （OR=2.06， 95%CI： 1.11-3.81，P=0.010）， serum carcinoembryonic antigen （CEA） （OR=1.87， 95%CI： 1.42-2.58，P=0.015）， and pleural invasion （OR=1.81， 95%CI： 1.07-3.07，P=0.021） were all independent influencing factors for the occurrence of lymph node metastasis in Ⅱa NSCLC patients. The C-index of the training set and the validation set were 0.91 （95%CI： 0.88-0.97） and 0.89 （95%CI： 0.84-0.96）， respectively， and the calibration curves of the two sets were well fitted to the ideal curves. Receiver operating characteristic curve analysis showed that， the area under curve of the nomogram prediction model used for differential diagnosis of patients in the training and validation sets were 0.92 （95%CI： 0.87-0.96） and 0.91 （95%CI： 0.85-0.98）， respectively. There were statistically significant differences in surgical time [（203.08±38.26） minvs.（177.14±22.18） min，t=5.59，P<0.001]， intraoperative blood loss [（458.14±65.04） mlvs.（426.08±26.58） ml，t=4.34，P<0.001]， thoracic drainage volume [（1 200.14±226.58） mlvs.（1 114.38±164.34） ml，t=2.92，P=0.004]， extubation time [（6.57±1.28） dvs.（5.02±1.12） d，t=8.71，P<0.001]， hospital stay [（15.02±1.29） dvs.（12.08±1.57） d，t=13.86，P<0.001） between the SML group and the LSND group in the training set. There was no statistically significant difference in OS rate between two groups of patients at 1 year （96.77%vs.96.67%）， 3 years （84.95%vs.86.67%）， and 5 years （75.27%vs.77.78%） （χ2=0.16，P=0.689）. There was a statistically significant difference in the overall incidence of adverse reactions [18.28%（17/93）vs.7.78%（7/90）] between two groups of patients （χ2=4.43，P=0.035）.ConclusionIntrapulmonary segment lymph node accounts for a considerable proportion in the metastasis process of NSCLC， with the highest degree of lymph node metastasis rate in groups 10， 11， and 12-13. Maximum tumor diameter， CT imaging features， degree of differentiation， serum CEA， and pleural invasion are all independent influencing factors for the occurrence of lymph node metastasis in NSCLC patients. Compared with SML， LSND has less trauma and a lower incidence of adverse reactions. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Trends of the use of proton beam radiation therapy in patients with central nervous system tumors： analysis of National Cancer Database (2004-2021） Saber Amin, Chi Lin Journal of International Oncology 2024, 51 (7): 424-431. DOI:10.3760/cma.j.cn371439-20240624-00070 Abstract（ 151） HTML（ 11） PDF（pc）（3492KB）（ 182） Knowledge map Save ObjectiveTo evaluate trends in the use of proton beam radiation therapy (PBT） in patients with central nervous system (CNS） tumors in the United States and the factors associated with such use.MethodsThe National Cancer Database was queried for CNS tumors patients between 2004 and 2021 to explore the time trend in the use of PBT by histology type， age at diagnosis， insurance， median household income level， education level， and hospital type. Multivariable logistic regression analysis was used to report the association of various factors with the use of PBT.ResultsOf all the 192 696 CNS patients， 5 901 （3.1%） received PBT， among whom 4 109 （69.6%） were ≥18 years of age. The use of PBT in CNS tumors increased from only 1.0% in 2004 to 11.4% in 2021. In patients who received PBT， embryonal tumor was the most common pediatric tumor while astrocytoma was most common adult tumor. Multivariable logistic regression analysis revealed that patients with glioblastoma， ependymoma， medulloblastoma， germinoma were more likely to received PBT compared to astrocytoma. Age<18 years， no-comorbidity， private insurance， higher household income level and being diagnosed in recent years were also positively associated with the use of PBT.ConclusionThe patients with younger age， no-comorbidity， higher household income， private insurance， diagnosed in recent years and certain tumor histologists are more likely to receive PBT in the United States. The use of PBT increased from 1.0% in 2004 to 11.4% in 2021. However， there is still a distinguished gap between the number of patients who should receive PBT and the number of patients who received PBT. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Effects of RRM2 on malignant biological behavior and aerobic glycolysis of gastric cancer cells by regulating CDK1 Tan Rongjian, Ou Wenting, Zhai Jiawei, Quan Zhenhao, Sun Lijun, Zhou Caijin Journal of International Oncology 2025, 52 (1): 23-30. DOI:10.3760/cma.j.cn371439-20240607-00003 Abstract（ 201） HTML（ 26） PDF（pc）（2249KB）（ 175） Knowledge map Save ObjectiveTo investigate the effect of ribonucleotide reductase regulatory subunit M2 （RRM2） on the malignant biological behavior and aerobic glycolysis of gastric cancer cells by regulating cyclin-dependent kinase （CDK） 1.MethodsHuman gastric cancer MKN-45 cells were divided into si-NC group （transfected with blank fragment）， CoCl2+si-NC group （hypoxia control transfected with blank fragment）， CoCl2+si-RRM2 group （hypoxia with RRM2 silencing）， CoCl2+si-RRM2+pcDNA3.1 NC group （hypoxia with RRM2 silencing and blank vector） and CoCl2+si-RRM2+pcDNA3.1 CDK1 group （hypoxia with RRM2 silencing and CDK1 overexpression）. The mRNA relative expression levels of RRM2 and CDK1 were analyzed by real time fluorescent quantitative reverse transcription PCR. Co-immunoprecipitation （CoIP） was used to analyze the interaction between RRM2 and CDK1 protein. MTT assay was used to analyze the proliferation activity of cells. The cell migration distance was detected by cell scratch assay. Cell apoptosis was detected by flow cytometry. Adenosine triphosphate （ATP） and glucose kit were used to detect ATP production and glucose consumption. The protein expressions of ENO1， RRM2， HK2， PKM2， GLUT1 and p-CDK1/CDK1 were detected by Western blotting.ResultsReal time fluorescent quantitative reverse transcription PCR results showed that the relative expression levels of CDK1 mRNA in si-NC group， CoCl2+si-NC group and CoCl2+si-RRM2 group were 1.01±0.15， 1.30±0.06 and 0.51±0.18， and the relative expression levels of RRM2 mRNA were 1.03±0.32， 1.59±0.28 and 0.44±0.17， respectively， and there were statistically significant differences （F=25.52，P=0.001；F=14.47，P=0.005）. The mRNA expressions of RRM2 and CDK1 in CoCl2+si-NC group were higher than those in si-NC group. Compared with the si-NC group and the CoCl2+si-NC group， the mRNA expressions of RRM2 and CDK1 were lower in the CoCl2+si-RRM2 group （allP<0.05）. CoIP results showed that there was interaction between RRM2 and CDK1. MTT assay， cell scratch assay and flow cytometry showed that the cell proliferation activity of si-NC group， CoCl2+si-NC group， CoCl2+si-RRM2 group， CoCl2+si-RRM2+pcDNA3.1 NC group and CoCl2+si-RRM2+pcDNA3.1 CDK1 group were 1.04±0.01， 1.18±0.04， 0.84±0.03， 0.81±0.03 and 0.93±0.05， respectively. The cell migration distances were （301.83±2.75）， （369.67±0.76）， （176.50±6.38）， （175.83±3.69）， （254.17±1.61） μm， respectively. The apoptosis rates were 8.05%±0.21%， 5.75%± 0.20%， 28.28%±0.04%， 30.18%±1.51% and 17.79%±0.22%， respectively， all with statistically significant differences （F=73.82，P<0.001；F=1 600.01，P<0.001；F=787.15，P<0.001）. Compared with the si-NC group and CoCl2+si-NC group， the proliferation and migration ability of cells in the CoCl2+si-RRM2 group， CoCl2+si-RRM2+pcDNA3.1 NC group and CoCl2+si-RRM2+pcDNA3.1 CDK1 group were weaker， and the apoptosis rates were higher （allP<0.05）. Compared with the CoCl2+si-RRM2+pcDNA3.1 NC group， the proliferation and migration ability of cells in the CoCl2+si-RRM2+pcDNA3.1 CDK1 group were stronger， and the apoptosis rate was lower （allP<0.05）. The results of ATP and glucose detection showed that there were statistically significant differences in the amount of ATP production and glucose consumption among the above five groups （F=12.53，P<0.001；F=19.21，P<0.001）. Compared with the si-NC group， the glucose consumption of cells was lower in the CoCl2+si-RRM2+pcDNA3.1 CDK1 group （P<0.05）. Compared with the CoCl2+si-NC group， the ATP production and glucose consumption of cells in the CoCl2+si-RRM2+pcDNA3.1 CDK1 group were lower （bothP<0.05）. Compared with the CoCl2+si-RRM2+pcDNA3.1 NC group， the ATP production and glucose consumption of the CoCl2+si-RRM2+pcDNA3.1 CDK1 group were higher （bothP<0.05）. Western blotting showed that there were statistically significant differences in the protein expressions of ENO1， RRM2， HK2， PKM2， GLUT1， and p-CDK1/CDK1 among the above five groups （allP<0.001）. Compared with the si-NC group and the CoCl2+si-NC group， the protein expressions of ENO1， RRM2， HK2， PKM2， GLUT1 and p-CDK1/CDK1 in the CoCl2+si-RRM2+pcDNA3.1 CDK1 group were lower （allP<0.05）. Compared with the CoCl2+si-RRM2+pcDNA3.1 NC group， the protein expressions of ENO1， RRM2， PKM2， GLUT1 and p-CDK1/CDK1 in the CoCl2+si-RRM2+pcDNA3.1 CDK1 group were higher （allP<0.05）.ConclusionsSilencing RRM2 can inhibit the malignant biological behavior of gastric cancer cells and the occurrence of aerobic glycolysis by regulating CDK1. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Expert consensus on the clinical diagnosis and treatment of post-obstructive pneumonia in newly diagnosed lung cancer patients Radiation Oncology Professional Committee of the Chinese Research Hospital Association, Hebei Society of Mathematical and Physical Medicine, Tianjin Precision Medicine Society Journal of International Oncology 2025, 52 (8): 484-494. DOI:10.3760/cma.j.cn371439-20250606-00083 Abstract（ 76） HTML（ 6） PDF（pc）（1029KB）（ 170） Knowledge map Save Pneumonia is a major contributor to morbidity and mortality in patients with lung cancer. Lung cancer complicated with obstructive pneumonia refers to a secondary infection that develops when a tumor partially or completely occludes an airway， causing inadequate ventilation of the distal lung parenchyma. Because of its complex pathogenesis and atypical clinical presentation， obstructive pneumonia frequently interferes with anticancer therapy and thus warrants heightened vigilance among clinicians. For patients presenting at initial diagnosis with concurrent obstructive pneumonia， balancing anti‐infective treatment against antitumor therapy is particularly critical. Drawing on the latest domestic and international literature and integrating recent advances in the field， this consensus offers 12 evidence-based recommendations addressing the pathogenesis， diagnostic criteria， prioritization of anti-infective versus antitumor interventions， and other common clinical challenges in managing lung cancer complicated by obstructive pneumonia， with the goal of optimizing therapeutic decision‐making for frontline clinicians. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Journal of International Oncology 2025, 52 (8): 470-483. DOI:10.3760/cma.j.cn371439-20250312-00082 Abstract（ 339） HTML（ 13） PDF（pc）（1051KB）（ 156） Knowledge map Save Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Construction of a nomogram prediction model for lung metastasis in elderly patients with clear cell renal cell carcinoma Li Tian, Wu Yang, Zhang Jiangming, Xi Chunsheng Journal of International Oncology 2024, 51 (12): 755-762. DOI:10.3760/cma.j.cn371439-20240910-00128 Abstract（ 114） HTML（ 42） PDF（pc）（1758KB）（ 150） Knowledge map Save ObjectiveTo discusse the influencing factors of lung metastasis in elderly patients （≥60 years old） with clear cell renal cell carcinoma （ccRCC） based on Surveillance， Epidemiology， and End Results （SEER） database， and to construct and evaluate the nomogram prediction model.MethodsThe SEER database was used to retrieve the data of elderly ccRCC patients from 2017 to 2021. The screened 8 183 ccRCC patients were randomly assigned to the training set （n=5 728） and the validation set （n=2 455） at a ratio of 7∶3 by using the software R4.4.1. The incidence of lung metastasis in elderly patients with ccRCC was calculated， and the influencing factors of lung metastasis in elderly patients with ccRCC were analyzed by univariate and multivariate logistic regression. According to the results of multivariate analysis， the nomogram prediction model was constructed， and the prediction efficiency of the model was evaluated by using the receiver operator characteristic （ROC） curve， the clinical application value of the prediction model was evaluated by calibration curve and decision curve analysis （DCA）.ResultsA total of 8 183 elderly ccRCC patients were retrieved， including 620 patients with lung metastasis， and the incidence of lung metastasis was 7.58%. Univariate analysis showed that， race （white race：OR=1.58， 95%CI： 1.01-2.49，P=0.046； others：OR=1.85， 95%CI： 1.10-3.10，P=0.020）， sex （OR=1.32， 95%CI： 1.07-1.64，P=0.009）， maximum tumor diameter （55-95 mm：OR=8.22， 95%CI： 6.11-11.07，P<0.001；>95 mm：OR=28.12， 95%CI： 20.81-37.99，P<0.001）， T stage （T2stage：OR=15.62， 95%CI： 11.51-21.19，P<0.001； T3stage：OR=7.93， 95%CI： 6.06-10.36，P<0.001； T4stage：OR=28.65， 95%CI： 18.71-43.86，P<0.001）， N stage （OR=17.18， 95%CI： 13.36-22.10，P<0.001） and surgery situation （OR=0.12， 95%CI： 0.09-0.14，P<0.001） were all influencing factors for lung metastasis in elderly patients with ccRCC. Multivariate analysis showed that， race （white race：OR=1.82， 95%CI： 1.07-3.09，P=0.027； others：OR=2.18， 95%CI： 1.17-4.05，P=0.014）， maximum tumor diameter （55-95 mm，OR=4.63， 95%CI： 3.13-6.86，P<0.001； >95 mm，OR=8.29， 95%CI： 5.28-13.02，P<0.001）， T stage （T2stage：OR=2.26， 95%CI： 1.45-3.51，P<0.001； T3stage：OR=3.38， 95%CI： 2.28-5.01，P<0.001； T4stage：OR=2.45， 95%CI： 1.39-4.31，P=0.002）， N stage （OR=3.81， 95%CI： 2.81-5.17，P<0.001） and surgery situation （OR=0.10， 95%CI： 0.08-0.14，P<0.001） were independent influencing factors of lung metastasis in elderly patients with ccRCC. According to the results of multivariate analysis， a nomogram prediction model was constructed based on race， maximum tumor diameter， T stage， N stage and surgery situation. ROC curve analysis showed that the area under the curve （AUC） of the prediction model in the training set and the validation set for predicting lung metastasis in ccRCC patients was 0.91 （95%CI： 0.90-0.92） and 0.91 （95%CI： 0.89-0.93）， respectively， which indicated that the prediction model had excellent distinguishing ability. Calibration curve showed that the actual occurrence probability of the training set and the validation set was consistent with the predicted probability， which showed that the calibration degree of the prediction model was good. DCA curve showed that the predictive model had good discrimination ability in both training set and validation set， which indicated that the predictive model had potential clinical application value.ConclusionThe incidence of lung metastasis in elderly patients with ccRCC is high. Race， maximum tumor diameter， T stage， N stage and surgery situation are all independent influencing factors of lung metastasis in elderly patients with ccRCC. The prediction model based on the above indexes has excellent prediction efficiency and clinical application value， and can be used to predict the risk of lung metastasis in elderly patients with ccRCC. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Progress in the study of the pregnane X receptor in drug resistance in breast cancer Han Xiaoxu, Zhang Nan, Liu Shuai Journal of International Oncology 2024, 51 (9): 590-594. DOI:10.3760/cma.j.cn371439-20240422-00098 Abstract（ 161） HTML（ 51） PDF（pc）（699KB）（ 135） Knowledge map Save The pregnane X receptor （PXR） is a crucial regulator of cytochrome P-450 （CYP450） expression. It is involved in oxidative stress， steroid and bile acid metabolism， inflammatory response， apoptosis， cell proliferation and other biological behaviors， and also participates in the metabolism， transport and clearance of chemotherapy drugs. After activation， PXR can affect chemotherapy drug resistance of breast cancer through genetic variation and epigenetic modification， regulation of apoptosis， and participation in phosphorylation/dephosphorylation. It may be a potential therapeutic target for patients with breast cancer resistance. Reference|Related Articles|Metrics|Comments（0）

Select

Advances in immunotherapy for breast cancer Sa Qiang, Xu Hangcheng, Wang Jiayu Journal of International Oncology 2024, 51 (4): 227-234. DOI:10.3760/cma.j.cn371439-20231017-00038 Abstract（ 285） HTML（ 17） PDF（pc）（764KB）（ 119） Knowledge map Save According to the latest global cancer burden data for 2020 released by the WHO's International Agency for Research on Cancer， breast cancer has become the malignant tumor with the highest incidence worldwide. Based on existing internal medicine treatment means like chemotherapy， targeted therapy and endocrine therapy， the development of immunotherapy provides novel solutions for the treatment of breast cancer. To date， the clinical research of immunotherapy in various molecular types and stages of breast cancer has reached certain achievements. In addition， the exploration of joint application with other therapies， predictive markers for efficacy， and immune-related adverse effects is also ongoing. The research and development in the field of breast cancer immunotherapy holds a promising prospect， and approaching research advances will promote the further application of immunotherapy in breast cancer. Table and Figures|Reference|Related Articles|Metrics|Comments（0）

Select

Research progress in precise molecular targeted therapy for advanced colorectal cancer Zhan Haifeng, Wang Wenxue, Geng Jiawei Journal of International Oncology 2024, 51 (9): 601-605. DOI:10.3760/cma.j.cn371439-20240522-00100 Abstract（ 170） HTML（ 41） PDF（pc）（699KB）（ 117） Knowledge map Save Colorectal cancer is a common malignant tumor of the digestive system， with the characteristics of insidious onset， high risk of recurrence and metastasis， and poor prognosis. In recent years， clinical researches related to targeted therapy for colorectal cancer of different molecular subtypes such as RAS， BRAF， MMR/MSI， HER2， MET， NTRK， and POLE/POLD1 have all achieved certain results. Besides， the exploration of the combined application of molecular targeted therapy for colorectal cancer and other therapies is also continuously carried out. Clarifying the mechanism of action and clinical application progress of molecular targeted therapy for colorectal cancer can provide a more reliable basis for formulating clinical treatment plans for colorectal cancer patients. Reference|Related Articles|Metrics|Comments（0）